Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial

NCT04615949 is registered in ClinicalTrials.gov with Cardiol Therapeutics Inc. as lead sponsor.

NCT NCT04615949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04615949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial
Lead sponsor
Cardiol Therapeutics Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
April 30, 2021
Completion date
November 30, 2022
Enrollment
90 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, cardiovascular risk factor, covid-19